Chemokine receptor-4 targeted PET/CT imaging with 68Ga-Pentixafor in head and neck cancer—a comparison with 18F-FDG and CXCR4 immunohistochemistry

Hadebe, Bawinile; Harry, Lerwine; Gabela, Lerato; Masikane, Siphelele; Patel, Maryam; Zwane, Sizwe; Pillay, Venesen; Bipath, Presha; Cebekhulu, Nonhlanhla; Nyakale, Nozipho E.; Ramdass, Prathima; Msimang, Mpumelelo; Aldous, Colleen; Sathekge, Mike Machaba; Vorster, Mariza

dc.contributor.author	Hadebe, Bawinile
dc.contributor.author	Harry, Lerwine
dc.contributor.author	Gabela, Lerato
dc.contributor.author	Masikane, Siphelele
dc.contributor.author	Patel, Maryam
dc.contributor.author	Zwane, Sizwe
dc.contributor.author	Pillay, Venesen
dc.contributor.author	Bipath, Presha
dc.contributor.author	Cebekhulu, Nonhlanhla
dc.contributor.author	Nyakale, Nozipho E.
dc.contributor.author	Ramdass, Prathima
dc.contributor.author	Msimang, Mpumelelo
dc.contributor.author	Aldous, Colleen
dc.contributor.author	Sathekge, Mike Machaba
dc.contributor.author	Vorster, Mariza
dc.date.accessioned	2024-12-13T06:44:16Z
dc.date.available	2024-12-13T06:44:16Z
dc.date.issued	2024-06
dc.description	DATA AVAILABITY STATEMENT: The raw data supporting the conclusions of this article will be made available by the authors on request.	en_US
dc.description.abstract	Please read abstract in article.	en_US
dc.description.department	Nuclear Medicine	en_US
dc.description.sdg	SDG-03:Good heatlh and well-being	en_US
dc.description.sdg	SDG-09: Industry, innovation and infrastructure	en_US
dc.description.sponsorship	The Nuclear Medicine Research Infrastructure (NuMeRi), the Discovery Foundation, and PentixaPharm AG, Berlin, Germany.	en_US
dc.description.uri	https://www.mdpi.com/journal/diagnostics	en_US
dc.identifier.citation	Hadebe, B.; Harry, L.; Gabela, L.; Masikane, S.; Patel, M.; Zwane, S.; Pillay, V.; Bipath, P.; Cebekhulu, N.; Nyakale, N.; et al. Chemokine Receptor-4 Targeted PET/CT Imaging with 68Ga-Pentixafor in Head and Neck Cancer—A Comparison with 18F-FDG and CXCR4 Immunohistochemistry. Diagnostics 2024, 14, 1375. https://doi.org/10.3390/diagnostics14131375.	en_US
dc.identifier.issn	2075-4418 (online)
dc.identifier.other	10.3390/diagnostics14131375
dc.identifier.uri	http://hdl.handle.net/2263/100007
dc.language.iso	en	en_US
dc.publisher	MDPI	en_US
dc.rights	© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https:// creativecommons.org/licenses/by/ 4.0/).	en_US
dc.subject	Pentixafor	en_US
dc.subject	SDG-03: Good health and well-being	en_US
dc.subject	SDG-09: Industry, innovation and infrastructure	en_US
dc.subject	Head and neck squamous cell carcinoma (HNSCC)	en_US
dc.subject	Positron emission tomography/computed tomography (PET/CT)	en_US
dc.subject	Human immunodeficiency virus (HIV)	en_US
dc.subject	Chemokine receptor 4 (CXCR4)	en_US
dc.title	Chemokine receptor-4 targeted PET/CT imaging with 68Ga-Pentixafor in head and neck cancer—a comparison with 18F-FDG and CXCR4 immunohistochemistry	en_US
dc.type	Article	en_US